Default company panoramic image

Tosk, Inc.

Tosk discovers and develops new drugs to improve outcomes for cancer patients by reducing adverse side effects of chemotherapeutic drugs.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Mountain View, CA, USA
  • Currency USD
  • Founded December 1998
  • Employees 5
  • Website

Company Summary

Tosk develops new drugs to improve outcomes for cancer patients by reducing the undesirable side effects of cancer chemotherapy. Tosk has developed two important side-effect-reducing agents, TK-90 for mucositis and TK-39 for cardiotoxicity. The Company has initiated human clinical studies for TK-90 and plans clinical studies for TK-39 in 2015. A product for pulmonary fibrosis is under development using Tosk's patented drug discovery platform.


  • Default avatar
    William Garland
    Vice Presient of Research and Develpoment

    Dr. Garland is a 35 year veteran of pharmaceutical discovery and development. Previously, Dr. Garland served as VP of Development at Lpath Therapeutics and VP of Scientific Affairs at Atairgin Technologies Inc., He served for 20 years at Roche, where he was Head of International Project Management. Dr. Garland received a BS in chemistry from the University of San Francisco and a Ph.D. in medicinal chemistry from the University of Washington.

  • Default avatar
    Steve Yanofsky
    Vice President Research

    Dr. Yanofsky is a cell biologist, pharmacologist, and project manager with more than 20 years’ experience in the pharmaceutical industry. Previously, he held positions of increasing responsibility in research with Affymax, Receptron, Multispan, and Amunix. At Affymax, he directed the high throughput screening group. He holds a Ph.D. in biochemistry from UC San Francisco, where he served as a post-doctoral student in Herbert Boyer’s laboratory.

  • Bea4221e 14ad 41f7 a368 459807745e7b

    Mr. Frenzel is a life science entrepreneur and investor. His previous experience includes co-founding and serving as the CEO or COO of four biomedical companies that achieved an exit for investors, either through IPO or acquisition. Previously, he was director of corporate planning for Syntex, a management consultant with Booz, Allen and the Boston Consulting Group, and an officer in the US Navy. He holds a BS in physics and an MBA from Stanford.


  • Default avatar
    Shawn Tacey, Esq.
    Default avatar
    Thomas Lindsay, CPA

Previous Investors

  • Default avatar
    Numa Capital
    Default avatar
    Rain Dance Capital
    Default avatar
    Family office and private equity investors